DALLAS — Multiple factors predicted improved survival among patients with head and neck or salivary gland cancers treated with pembrolizumab plus vorinostat, according to prospective study results.
Patients with lower pretreatment neutrophils and neutrophil-to-lymphocyte ratios — as well as those with more pretreatment lymphocytes and T helper cells — achieved longer OS and PFS, findings presented at American Head & Neck Society Annual Meeting showed.
Lower baseline neutrophil-to-lymphocyte ratios also appeared associated with reduced risk for serious adverse events.
“There